$2.42
-0.55 (-18.52%)
Open$2.91
Previous Close$2.97
Day High$2.91
Day Low$2.40
52W High$12.30
52W Low$1.31
Volume—
Avg Volume67.5K
Market Cap5.77M
P/E Ratio—
EPS$-6.72
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+1,044.2% upside
Current
$2.42
$2.42
Target
$27.69
$27.69
$21.92
$27.69 avg
$40.08
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.17M | 2.19M | 3.54M |
| Net Income | -41,182,595 | -37,299,321 | -86,327 |
| Profit Margin | -1,893.6% | -1,798.9% | -2.4% |
| EBITDA | -40,014,439 | -38,254,721 | -134,724 |
| Free Cash Flow | — | — | -61,141 |
| Rev Growth | -0.6% | -0.6% | +8.8% |
| Debt/Equity | — | — | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $465.12 | -0.42% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $168.34 | +0.23% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $538.08 | -0.84% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $955.02 | +0.40% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $164.26 | +4.86% | 7.7 | 20.98B |